Detection of lymph node metastases with ultrasmall super paramagnetic iron oxide (USPIO)-enhanced magnetic resonance imaging in oesophageal cancer: A feasibility study

Cancer Imaging

Volumn 9, Issue 1, 2009, Pages 19-28

  Pultrum, B B ^a   van der Jagt, E J ^a   van Westreenen, H L ^a   van Dullemen, H M ^a   Kappert, P ^a   Groen, H ^a   Sietsma, J ^a   Oudkerk, M ^a   Plukker, J Th M ^a   van Dam, G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Lymph node staging; Oesophageal cancer; Oesophagectomy; Ultra small superparamagnetic iron oxide (USPIO) enhanced magnetic resonance imaging (MRI)

Indexed keywords

FLUORODEOXYGLUCOSE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

AGED; CONTRAST MEDIA; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE ENHANCEMENT; IRON; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXIDES;

EID: 65549130609     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2009.0004     Document Type: Article

References (28)

1. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72: 306-313. doi:10.1016/ S0003-4975(00)02570-4. PMid:11465217.
2. Quint LE, Bogot NR. Staging esophageal cancer. Cancer Imaging 2008; 8 Suppl A: S33 S42. doi:10.1102/1470-7330.2008.9007.
3. Iyer R, Dubrow R. Imaging of esophageal cancer. Cancer Imaging 2004; 4: 125-132. doi:10.1102/1470-7330.2004.0022.
4. Lightdale CJ. Esophageal cancer. American College of Gastroenterology. Am J Gastroenterol 1999; 94: 20-29. doi:10.1111/j.1572-0241.1999.00767.x.
5. Pultrum BB, van Westreenen HL, Mulder NH, van Dullemen HM, Plukker JT. Outcome of palliative care regimens in patients with advanced oesophageal cancer detected during explorative surgery. Anticancer Res 2006; 26: 2289-2293.
6. van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt EJ, Jager PL, Groen H, Plukker JT. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 2005; 9: 54-61. doi: 10.1016/j.gassur.2004.09.055.
7. Chandawarkar RY, Kakegawa T, Fujita H, Yamana H, Hayabuthi N. Comparative analysis of imaging modalities in the preoperative assessment of nodal metastasis in esophageal cancer. J Surg Oncol 1996; 61: 214-217. doi: 10.1002/ (SICI)1096-9098(199603)61:3<214::AID-JSO10>3.0.CO;2-7.
8. Flamen P, Lerut A, Van CE, De WW, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De LP, Van RD, Coosemans W, Ectors N, Haustermans K, Mortelmans L. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-3210.
9. Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006; 19: 433-442. doi:10.1111/j.1442-2050.2006.00617.x.
10. van Westreenen HL, Heeren PA, Jager PL, van Dullemen HM, Groen H, Plukker JT. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol 2003; 10: 1100-1105. doi:10.1245/ASO.2003.03.005.
11. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: its role in clinical management. Radiographics 2007; 27: 1635-1652. doi:10.1148/rg.276065742.
12. Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, Saini S, Maravilla KR, Feldman DE, Schmiedl UP, Brunberg JA, Francis IR, Harms SE, Som PM, Tempany CM. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003; 228: 777-788. doi:10.1148/ radiol.2283020872.
13. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la RJ, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499. doi:10.1056/NEJMoa022749.
14. Nguyen BC, Stanford W, Thompson BH, Rossi NP, Kernstine KH, Kern JA, Robinson RA, Amorosa JK, Mammone JF, Outwater EK. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging 1999; 10: 468-473. doi:10.1002/ (SICI)1522-2586(199909)10:3<468::AID-JMRI31>3.3.CO;2-9.
15. Stets C, Brandt S, Wallis F, Buchmann J, Gilbert FJ, Heywang-Kobrunner SH. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imaging 2002; 16: 60-68. doi:10.1002/jmri.10134.
16. Barentsz JO, Futterer JJ, Takahashi S. Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol 2007; 63: 369-372. doi:10.1016/ j.ejrad.2007.06.025.
17. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58: 1471-1504. doi:10.1016/j.addr.2006.09.013.
18. Deserno WM. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233: 449-456. doi:10.1148/radiol.2332031111.
19. Koh DM, Brown G, Temple L, Raja A, Toomey P, Bett N, Norman AR, Husband JE. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings-initial observations. Radiology 2004; 231: 91-99. doi:10.1148/radiol.2311030142.
20. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175: 494-498.
21. Will O, Purkayastha S, Chan C, Athanasiou T, Darzi AW, Gedroyc W, Tekkis PP. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 2006; 7: 52-60. doi:10.1016/ S1470-2045(05)70537-4.
22. Nishimura H, Tanigawa N, Hiramatsu M, Tatsumi Y, Matsuki M, Narabayashi I. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg 2006; 202: 604-611. doi:10.1016/ j.jamcollsurg.2005.12.004.
23. Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 2007; 63: 401-407. doi:10.1016/j.ejrad.2007.02.010.
24. Sigal R. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) - results of a phase-III multicenter clinical trial. Eur Radiol 2002; 12: 1104-1113. doi:10.1007/s003300101130.
25. Shen T, Weissleder R, Papisov M, Bogdanov A, Jr., Brady TJ. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med 1993; 29: 599-604. doi:10.1002/mrm.1910290504.
26. Hudgins PA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. Am J Neuroradiol 2002; 23: 649-656.
27. Rety F, Clement O, Siauve N, Cuenod CA, Carnot F, Sich M, Buisine A, Frija G. MR lymphography using iron oxide nanoparticles in rats: pharmacokinetics in the lymphatic system after intravenous injection. J Magn Reson Imaging 2000; 12: 734-739. doi:10.1002/ 1522-2586(200011)12:5<734::AID-JMRI10>3.0.CO;2-R.
28. Pannu HK, Wang KP, Borman TL, Bluemke DA. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 2000; 12: 899-904. doi:10.1002/ 1522-2586(200012)12:6<899::AID-JMRI13>3.0.CO;2-R.